Trial Profile
A randomized, double-blind, placebo-controlled dose selection study with two RP 01 formulations evaluating anti-IgE immunotherapy in allergic patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs RP 01 (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Resistentia Pharmaceuticals
- 09 Jun 2011 New trial record